ReviewFuture oncology (London, England)2025

Beyond the status quo: when disease volume and metastatic timing are not enough to personalize treatment in mHSPC.

Ángel Borque-Fernando et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.